OOIR: Observatory of International Research

Papers

(The H4-Index of Experimental Hematology & Oncology is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	262
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	199
Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia	164
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	145
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	134
Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmu	131
Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma	117
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	112
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	107
From Amphiphiles to mRNA platforms: emerging vaccination strategies for pancreatic cancer	106
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	93
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	92
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	91
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	89
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	88
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	85
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	79
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	77
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	75
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	74
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	69
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	69
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	67
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy	67
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	65

All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	64
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	63
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	63
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	58
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting	57
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	57
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	56
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	54
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	54
Breast cancer heterogeneity and its implication in personalized precision therapy	52
Role of m6A writers, erasers and readers in cancer	51
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	50
Three-dimensional chromatin landscapes in MLLr AML	50
The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND8	50
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma	48
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	47
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	45
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	44